16th Biosimilars Congregation 2021

“Uniting industry leaders to analyse advanced commercial developments & identify successful management strategies of Biosimilars”

09th December 2021, Virtual Conference (Time Zone – IST)

The global biosimilars market size is expected to grow from USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7%. However, with complexities in manufacturing and resistance from biologic manufacturers, such factors keep adding to the hindrance in their development.

2030, India will become the sixth-largest market for pharmaceuticals, and it has firmly established itself in the global biopharmaceutical market. Many of the Indian pharmaceutical companies are preparing to step into the global biosimilars market. As per the report of 2017, biosimilars represent a 30% compound annual growth rate. They are worth $2.2bn out of the $32bn total Indian pharma market and are estimated to reach $40bn by the year 2030.

Virtue Insight is delighted to invite you to attend the 16th Biosimilars Congregation 2021 conference, to be held on 09th December 2021(Virtual Conference). 16th Biosimilars Congregation 2021 brings together scientists, researchers and CROs from around the world.

At 16th Biosimilars Congregation 2021 meet your target audiences from around the world focused on learning about biologics and biosimilars. This conference would be your single best opportunity to reach the largest assemblage of participants from the biologics and biosimilars community

DELEGATE REGISTRATION:

E-mail - bookings@virtueinsight.com or Call - + 91 44 42108101

Standard Price - (INR 8,000 + GST (18%) per delegate)

Conference Sponsor, Exhibition Stall & Paid Speaker Slot - Please email your interest and queries to bookings@virtueinsight.com

KEY SPEAKERS:

ARANI CHATTERJEE, Senior Vice President, Clinical Research, Aurobindo
PHILIP SCHNEIDER, Chair, International Advisory Board, Alliance for Safe Biologic Medicines(USA)
MICHEL MIKHAIL, International Expert in Regulatory Affairs, Global Expert in Biosimilars (Germany)
RAHUL GUPTA, Vice President, Regulatory Affairs, USV
MARTA BALDRIGHI, Policy and Science Officer, Medicines for Europe (Belgium)
SHALIGRAM RANE, Vice President of Quality, Lupin
NARENDRA MAHARAJ, Vice President and Head, Clinical Development and Biologics, Dr. Reddy's Laboratories
PRAVIN KULKARNNI, Vice President – Quality (Biotech), Wockhardt
PRAVEEN KUMAR L, Director - Regulatory Affairs, Cipla
SAMIR KULKARNI, Director, National Center for Nano-science and Nanotechnology
PIRTHI PAL SINGH, Vice President, Tirupati Group
PAWAN SINGH, Senior Medical Director, Biocon
KUMAR GAURAV, Director Medical Affairs, Dr. Reddy's Laboratories
MILIND ANTANI, Leader, Pharma and Healthcare, Nishith Desai Associates
ARUN BHATT, Consultant – Clinical Research & Development
NITISH CHAKRAVARTY, Vice President - Secondary Manufacturing, Biological E. Limited
KANTHIKIRAN VARANASI, Vice President and Head - Clinical Research & Operations, Galenicum
GAURAV SAHAL, Head of Global Patent Prosecution, Sun Pharma
ADITYA SHARMA, Head - BioProcessing Business, Merck Life Science
NIBEDITA RATH, Scientific Director, Open Source Pharma Foundation
UDIT SAKHUJA, Head Of Marketing, Dr. Reddy's Laboratories
SONAL SHAH, Head Marketing – Biosimilars, Cadila
MANISH MAHAJAN, DGM- Medical Affairs, Cadila Healthcare (BU- Biologics)
SWEETY MATHEW, Global Regulatory Affairs, Biocon
RAHUL CHAUHAN, Head- Regulatory Affairs, Takeda
NAGENDRA RMAMANJINAPPA, Medical Affairs, Viatris
ALOK SHARMA, Head & GM, Quality Control, Lupin
TUSHAR NAIK, Consultant & Advisor, GLG(USA) (Former Senior GM, Zydus Group)
RAVI SHANKARA, Senior General Manager (R & D) & Functional Head -Analytical Development - Biologics and Peptides, Sun Pharma
MAHENDRA SHIRADKAR, Lead: FDS Project and Portfolio Management, Viatris
PRAVIN A. NAIR, Head Drug Product Development (R&D), Intas Pharmaceuticals (Biopharma Division)
KAVYA KADAM, Consultant, Global Clinical Trials
HARSHAD KOTHAWADE, Head-Regulatory Management & Trade Compliance, Merck

KEY THEMES DISCUSSED:

Recent trends and new normal in Biosimilars - How to excel with this?
Development challenges on the biosimilars products for companies? What are the remedies?
Pharmacovigilance and risk management of biosimilars.
Successful business models and dealing with every ambiguity mAbs - Could be a game changer in India
Impact of the pandemic - affecting the biosimilar markets
Ways for smart handling of market access, sustainable pricing and reimbursement of biosimilars in the market.
Challenges and changes interchangeability
How does strategic planning really help to grow market opportunities?
Market barriers for biosimilar approval in India market.
Future opportunities for product development
Risk of adverse effects related to new drug development. How to overcome that?
Newer versions of generic drugs truly increase the value of the market?
How to speed up the process of development and reduce costs of production?
Regulators view on interchangeability and switching biosimilars.
How to minimise the rejection of biosimilar applications while evaluating regulatory bodies?
Next 5 years in the field of biosimilars regulations

WHO SHOULD ATTEND AND WHO YOU’LL MEET:

CSOs, CMOs, Vice Presidents, Presidents, Heads, Directors, Team Leaders, and Senior Scientists from the following roles:

Biopharmaceuticals/Biotherapeutics, Follow on Biologics/Follow on Proteins, Biologics/Biotechnology/ Bio generics, Legal Affairs, Intellectual Property, Health Economics, Pricing and Reimbursement, Clinical Immunology, Principal Scientist, Chief Scientific Officer, Process Control and Analytical Technologies, Analytical Characterisation, Regulatory Compliance, Pharmacovigilance, Drug Safety & Risk Management, Quality Affairs/ Quality Control, New Product Development, Process Science, Portfolio Management, Research & Development, Business Development, Business Operations, Scientific Affairs, Commercial Affair

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.

16th Biosimilars Congregation 2021

Event Information

Venue

Learn More

About

Organize Events